From Benzinga's Biotech Conference: Prenetics Global Co-Founder & CEO, Danny Yeung Says Co Is Going To Launch Liquid Version Of Tissue Based Testing, Says We Are Making Significant Steps With ACT'
Portfolio Pulse from Benzinga Newsdesk
Prenetics Global Co-Founder & CEO, Danny Yeung, announced at Benzinga's Biotech Conference that the company is planning to launch a liquid version of tissue-based testing. He also mentioned that they are making significant progress with ACT.
August 04, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prenetics Global is launching a liquid version of tissue-based testing, which could potentially increase the company's market share in the biotech industry.
The launch of a new product, especially one that could potentially revolutionize the industry, is likely to have a positive impact on the company's stock. This is because it could increase the company's market share and revenues, leading to higher profits.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100